Koumine exerts its anti-colorectal cancer effects by disrupting the interaction between HSP90 and CDC37, thereby downregulating downstream signaling pathways.
[BACKGROUND] Koumine, a principal bioactive alkaloid derived from the traditional Chinese herb , has demonstrated broad cytotoxic activity against various cancer cell lines.
APA
Lin H, Bao Y, et al. (2025). Koumine exerts its anti-colorectal cancer effects by disrupting the interaction between HSP90 and CDC37, thereby downregulating downstream signaling pathways.. Frontiers in oncology, 15, 1687690. https://doi.org/10.3389/fonc.2025.1687690
MLA
Lin H, et al.. "Koumine exerts its anti-colorectal cancer effects by disrupting the interaction between HSP90 and CDC37, thereby downregulating downstream signaling pathways.." Frontiers in oncology, vol. 15, 2025, pp. 1687690.
PMID
41635407
Abstract
[BACKGROUND] Koumine, a principal bioactive alkaloid derived from the traditional Chinese herb , has demonstrated broad cytotoxic activity against various cancer cell lines. However, its specific anti-tumor efficacy and underlying molecular mechanisms in colorectal cancer (CRC) remain largely unexplored.
[METHODS] We employed an integrated strategy combining network pharmacology prediction with experimental validation. Bioinformatics analysis was conducted to identify potential targets. In vitro functional assays were performed to evaluate effects on cell proliferation, clonogenicity, apoptosis, migration, and invasion. Target engagement was confirmed by cellular thermal shift assay (CETSA), and the molecular mechanism was investigated through Western blot and co-immunoprecipitation analyses.
[RESULTS] Network pharmacology identified heat shock protein 90 (HSP90) as a key potential target, a finding supported by molecular docking simulations. Koumine significantly inhibited the malignant phenotypes of CRC cells. CETSA confirmed direct binding of koumine to HSP90. Mechanistically, koumine disrupted the functional interaction between HSP90 and its co-chaperone CDC37, leading to the downregulation and inactivation of critical downstream client proteins, including cyclin-dependent kinases CDK4 and CDK6.
[DISCUSSION] These findings elucidate that koumine exerts potent anti-CRC effects primarily by targeting the HSP90-CDC37 chaperone complex and inhibiting the CDK4/6-Rb signaling axis. This study provides a robust mechanistic foundation and compelling preclinical evidence for the further development of koumine as a promising therapeutic agent for colorectal cancer.
[METHODS] We employed an integrated strategy combining network pharmacology prediction with experimental validation. Bioinformatics analysis was conducted to identify potential targets. In vitro functional assays were performed to evaluate effects on cell proliferation, clonogenicity, apoptosis, migration, and invasion. Target engagement was confirmed by cellular thermal shift assay (CETSA), and the molecular mechanism was investigated through Western blot and co-immunoprecipitation analyses.
[RESULTS] Network pharmacology identified heat shock protein 90 (HSP90) as a key potential target, a finding supported by molecular docking simulations. Koumine significantly inhibited the malignant phenotypes of CRC cells. CETSA confirmed direct binding of koumine to HSP90. Mechanistically, koumine disrupted the functional interaction between HSP90 and its co-chaperone CDC37, leading to the downregulation and inactivation of critical downstream client proteins, including cyclin-dependent kinases CDK4 and CDK6.
[DISCUSSION] These findings elucidate that koumine exerts potent anti-CRC effects primarily by targeting the HSP90-CDC37 chaperone complex and inhibiting the CDK4/6-Rb signaling axis. This study provides a robust mechanistic foundation and compelling preclinical evidence for the further development of koumine as a promising therapeutic agent for colorectal cancer.
같은 제1저자의 인용 많은 논문 (5)
- Vascularized iliac crest free flap in maxillofacial reconstruction: Pearls and pitfalls from 437 clinical application.
- The prognostic value of tumor macroscopic morphology in colorectal cancer.
- A pH-Responsive Controlled Release Platform Based on Honeycomb MnO/Carboxymethyl Chitosan/Oxidized Hyaluronic Acid for Multimodal Therapy of Breast Cancer.
- Discovery of 1,2,3,4-Tetrahydrochromeno[3,4-]pyridin-5-one Derivatives as Novel MTHFD Inhibitors for the Treatment of Acute Myeloid Leukemia.
- A cyclometalated iridium(III) complex induces paraptotic cell death via mitochondrial dysfunction and ER stress in triple-negative breast cancer cells.